Stocksigma LogoStocksigma Logo

Accretion Pharmaceuticals Posts Robust H1 FY27 Performance with PAT Surging 72.63% YoY

Accretion Pharmaceuticals reported a 25.83% YoY increase in net revenue to ₹55.04 crore for H1 FY27 ending 30th Sep'26, driven by volume growth and an

Accretion Pharmaceuticals Posts Robust H1 FY27 Performance with PAT Surging 72.63% YoY

Accretion Pharmaceuticals Ltd · Press Release · 31 Oct 2026, 10:53 pm

Accretion Pharmaceuticals Posts Robust H1 FY27 Performance with PAT Surging 72.63% YoY Accretion Pharmaceuticals reported a 25.83% YoY increase in net revenue to ₹55.04 crore for H1 FY27 ending 30th Sep'26, driven by volume growth and an improved product mix. EBITDA grew 72.28% YoY to ₹12.37 crore, with EBITDA margin expanding 606 bps to 22.48%. PAT jumped 72.63% YoY to ₹8.20 crore, expanding PAT margin by 403 bps to 14.90%. Basic EPS rose to ₹7.38 from ₹4.61 in H1 FY26. Export revenue contribution nearly doubled to 18.15% from 9.16% YoY.

Original exchange filing (PDF)

More announcements from Accretion Pharmaceuticals Ltd

All Accretion Pharmaceuticals Ltd announcements